Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2020.04.105
Abstract: Antineoplastic agents that utilize the immune system have revolutionized cancer treatment. Specifically, implementation of immune checkpoint inhibitors, monoclonal antibodies that block cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed death… read more here.
Keywords: immune checkpoint; review; histopathologic features; dermatologic toxicities ... See more keywords
Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Women's Dermatology"
DOI: 10.1097/jw9.0000000000000073
Abstract: Background: Minority patients are more likely to require dose adjustments for chemotherapy, with cultural barriers and access to medical care cited as contributory factors. Objective: We sought to pilot an educational intervention, in the form… read more here.
Keywords: toxicities chemotherapy; educational intervention; dermatologic toxicities; skin color ... See more keywords
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Cutaneous Pathology"
DOI: 10.1111/cup.12858
Abstract: Immunomodulatory drugs that leverages host immune mechanisms to destroy tumor cells have been met with great promise in the treatment of cancer. Immunotherapy, targeting cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4) and the programmed cell death 1… read more here.
Keywords: immune checkpoint; diverse types; patients receiving; types dermatologic ... See more keywords